계정 가입
이미 존재한 계정
가입을 클릭하여 코인타임의 <a class="underline" href="#term-of-service">서비스 약관</a> 과 a class="underline" href="#privacy-policy">개인정보 보호 정책</a> . 에 동의함.
email 로 로그인
email 로 가입
사용자 이메일
수신함을 확인하세요
중의 링크를 통해 로그인 하세요
중의 링크를 통해 가입 하세요
Chiasma
company
About
Chiasma is a biopharmaceutical company developing oral drugs for the treatment of orphan diseases.
- 51 - 100
Details
- Last Funding Type
- Series D
- Last Funding Money Raised
- $38.50M
- Industries
- Biopharma,Biotechnology,Therapeutics
- Founded date
- Jan 1, 2001
- Number Of Employee
- 51 - 100
- Operating Status
- Active
Chiasma applies its proprietary technology to approved drugs, which not only enables their being switched from injectable to oral, but importantly can result in new indications and/or enhanced absorption. The Company's Transient Permeability Enhancer technology promotes the delivery of drugs to the GI wall and from there to the liver. It is applicable to macromolecules that to-date can be administered only by injection. TPE can be utilized also with small molecules that are already orally available but are poorly absorbed.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
4
$152.50M
Chiasma has raised a total of
$152.50M
in funding over 2 rounds. Their latest funding was raised on
Feb 27, 2015 from a Series E round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Feb 27, 2015 | Series E | $70M | 1 | — | — | Detail |
| Jul 23, 2012 | Series D | $38.50M | 1 | — | — | Detail |
| Nov 15, 2006 | Series C | $44M | 1 | — | — | Detail |
| Jan 1, 2004 | Series A | — | 1 |
|
— | Detail |
Investors
Number of Lead Investors
Number of Investors
1
2
Chiasma is funded by 2 investors.
Innomed Ventures
and ARCH Venture Partners
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
|
Yes | Series A |
ARCH Venture Partners
|
— | Series E |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
